Advertisement
Advertisement
ANIP
ANI Pharmaceuticals, Inc.
67.41
USDSponsored
-2.21
-3.17%
Nov 06, 15:59 UTC -5
Closed
After-Market
67.34
-0.07
-0.10%
ANI Pharmaceuticals, Inc. (ANIP) Earnings
ANIP Earnings Reports
Positive Surprise Ratio
ANIP beat 30 of 44 last estimates.
68%
Next Report
Date of Next Report
Feb 25, 2027
Estimate for Q4 26 (Revenue/ EPS)
$325.65M
/$2.87
Implied change from Q3 26 (Revenue/ EPS)
+11.99%
/+6.30%
Implied change from Q4 25 (Revenue/ EPS)
+31.81%
/+23.18%
ANI Pharmaceuticals, Inc. earnings per share and revenue
On Nov 05, 2026, ANIP reported earnings of 2.70 USD per share (EPS) for Q3 26, beating the estimate of 2.22 USD, resulting in a 21.37% surprise. Revenue reached 290.78 million, compared to an expected 285.80 million, with a 1.74% difference. The market reacted with a -2.83% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of 2.87 USD, with revenue projected to reach 325.65 million USD, implying an increase of 6.30% EPS, and increase of 11.99% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Novavax Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.19
Surprise
+44.56%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
Castle Biosciences, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.13
Surprise
+65.32%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.29
Actual
$0.03
Surprise
+110.09%
PUMA BIOTECHNOLOGY INC
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.15
Surprise
+63.40%
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.26
Surprise
+62.44%
Anika Therapeutics Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
$0.06
Actual
$0.28
Surprise
+373.86%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Vera Therapeutics, Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.65
Actual
-$1.30
Surprise
+21.33%
FAQ
What were ANI Pharmaceuticals, Inc.'s earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, ANI Pharmaceuticals, Inc. reported EPS of $2.70, beating estimates by 21.37%, and revenue of $290.78M, 1.74% above expectations.
How did the market react to ANI Pharmaceuticals, Inc.'s Q3 2026 earnings?
The stock price moved down -2.83%, changed from $71.65 before the earnings release to $69.62 the day after.
When is ANI Pharmaceuticals, Inc. expected to report next?
The next earning report is scheduled for Feb 25, 2027.
What are the forecasts for ANI Pharmaceuticals, Inc.'s next earnings report?
Based on --
analysts, ANI Pharmaceuticals, Inc. is expected to report EPS of $2.87 and revenue of $325.65M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.